- Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024
- Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
- Rhythm Pharmaceuticals Announces New Employment Inducement Grants
- Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update
- Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
- Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
- Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
- Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing
- Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist
- Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences
More ▼
Key statistics
On Friday, Rhythm Pharmaceuticals Inc (RYTM:NMQ) closed at 39.97, -23.97% below its 52-week high of 52.57, set on Feb 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 39.20 |
---|---|
High | 40.50 |
Low | 38.85 |
Bid | 35.00 |
Offer | 41.74 |
Previous close | 39.68 |
Average volume | 501.32k |
---|---|
Shares outstanding | 60.97m |
Free float | 57.38m |
P/E (TTM) | -- |
Market cap | 2.35bn USD |
EPS (TTM) | -4.62 USD |
Data delayed at least 15 minutes, as of Jun 07 2024 21:00 BST.
More ▼